ClinicalTrials.gg
Status unknownNCT04885426Updated May 13, 2021

Metformin for the Prevention of CRA Recurrence

An interventional study of low-dose metformin and high-dose metformin in Colorectal Adenoma, Metformin and Chemoprevention, sponsored by Jing-yuan Fang, MD, Ph. D. Status unknown at 1 site in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-05-13.

Sponsored by Jing-yuan Fang, MD, Ph. D · Not applicable, Interventional, and Prevention

How we know

The sponsor has not verified this record recently (last verified May 2021), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Aug 2020, registered Nov 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
414
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Study summary

Most of the sporadic colorectal cancer (CRC )develop from colorectal adenoma (CRA), patients with CRA have a high risk of recurrence and development of metachronous CRA or CRC after removal, therefore, the investigators conducted this clinical trial to explore the chemoprevetion effect of metformin for CRA recurrence after removal.

Read the detailed description

Colorectal adenomas are well-known to be precancerous lesions that develop into colorectal cancers on the basis of the adenoma-carcinoma sequence. The effects of screening for colorectal adenomas and removing precancerous lesions on the prevention of colorectal cancer have been established. Because of the high recurrence rates of colorectal adenomas in patients who have undergone polypectomy, the potential chemopreventive agents that may reduce the risk of colorectal adenoma recurrence need to be investigated.

Metformin is a widely used diabetes medicine. In recent years, anticancer activity of metformin has been explored. The aim of this study is to investigate the effect of metformin on the recurrence of colorectal adenomas by conducting a randomized, placebo-controlled, prospective clinical.

02

Conditions studied

  • Colorectal Adenoma
  • Metformin
  • Chemoprevention
03

In context

Lead sponsor

Jing-yuan Fang, MD, Ph. D is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 40-80 years without diabetes;
  2. CRAs removed without recurrence before recruitment;
  3. Must sign the consent form after being fully informed and understanding the purpose and procedure of this study.

Exclusion criteria

Exclusion Criteria:

  1. Familial adenomatous polyposis (FAP) or hereditary non-polyposis colorectal cancer (HNPCC, Lynch syndrome);
  2. Regularly taking aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), cyclo-oxygenase 2 (COX2) inhibitors, calcium or vitamin D;
  3. Have a history of gastrointestinal surgery;
  4. Have severe heart, liver or kidney disease ;
  5. Have cancer history;
  6. Women with pregnant, during breast-feeding period, or with expect pregnancy;
  7. Diabetes(taking diabetes medicines or >6.5%);
  8. Inflammatory bowel disease;
  9. Mental illness;
  10. Intolerant to metformin;
  11. Cannot tolerate colonoscopy;
  12. Staffs in this clinical trial;
  13. Poor bowel preparation for colonoscopy or the examination time is shorter than 6 minutes;
  14. Unsuitable for inclusion by the investigator
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
414 participants (estimated)

Study arms

  • Experimental
    low-dose metformin group

    low-dose metformin, 250mg/day

    Drug: low-dose metformin

  • Experimental
    high-dose metformin group

    high-dose metformin, 500mg/day

    Drug: high-dose metformin

  • Placebo comparator
    control group

    placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. CRA recurrence rate

    Percentage of patients who has recurrence of CRA(colorectal adenoma) during or after chemotherapy with metformin or placebo.

    Time frame: one year, two years

Secondary outcomes

  1. All polypoid lesions incidence rate

    Percentage of patients who has incidence of all polypoid lesions during or after chemotherapy with metformin or placebo.

    Time frame: one year, two years

  2. CRC incidence rate

    Percentage of patients who has incidence of CRC (colorectal cancer) during or after chemotherapy with metformin or placebo.

    Time frame: one year, two years

07

Study locations

1 of 1 sites recruiting
  • Division of Gastroenterology and Hepatology, Ren-Ji Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai Institute of Digestive Disease; Key Laboratory of Gastroenterology & Hepatology, Ministry of Health
    Shanghai, Shanghai 200001, China
    Recruiting
    • Jing-Yuan Fang, MD. Ph D. · Contactwangjilin811123@163.com · +863386235037
    • Jing-Yuan Fang, MD. Ph D. · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2020 (actual). Primary completion is estimated for Nov 2022, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2020
First posted
May 13, 2021
StartActual
Aug 1, 2020
Primary completionEst.
Nov 2022
CompletionEst.
Nov 2022
Last update
May 13, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04885426
Lead sponsor
Jing-yuan Fang, MD, Ph. D
Responsible party
Jing-yuan Fang, MD, Ph. D (Director of Department of Gastroenterology, Shanghai Jiao Tong University School of Medicine) — Sponsor-investigator
First posted
May 13, 2021
Start date
Aug 1, 2020
Primary completion
Nov 2022 (estimated)
Completion
Nov 2022 (estimated)
Last update
May 13, 2021

Study contacts

Jing-Yuan Fang, Professor
Contact
jingyuanfang@sjtu.edu.cn
+8613918386561
Jing-Yuan Fang, Professor
study director · Shanghai Jiao Tong University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion